Harvard Bioscience Inc [NASDAQ: HBIO] closed the trading session at $0.48 on 2025-09-16. The day’s price range saw the stock hit a low of $0.4526, while the highest price level was $0.56.
The stocks have a year to date performance of -82.62 percent and weekly performance of 10.83 percent. The stock has been moved at -30.24 percent over the last six months. The stock has performed -8.34 percent around the most recent 30 days and changed -4.77 percent over the most recent 3-months.
If compared to the average trading volume of 843.86K shares, HBIO reached to a volume of 11417836 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Harvard Bioscience Inc [HBIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HBIO shares is $2.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HBIO stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
KeyBanc Capital Markets have made an estimate for Harvard Bioscience Inc shares, keeping their opinion on the stock as Sector Weight, with their previous recommendation back on April 09, 2025. While these analysts kept the previous recommendation, The Benchmark Company raised their target price from $3 to $4. The new note on the price target was released on March 10, 2023, representing the official price target for Harvard Bioscience Inc stock.
The Price to Book ratio for the last quarter was 1.37, with the Price to Cash per share for the same quarter was set at 0.17. Price to Free Cash Flow for HBIO in the course of the last twelve months was 4.90 with Quick ratio for the last quarter at 0.41.
HBIO stock trade performance evaluation
Harvard Bioscience Inc [HBIO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 10.83. With this latest performance, HBIO shares dropped by -8.34% in over the last four-week period, additionally sinking by -30.24% over the last 6 months – not to mention a drop of -77.02% in the past year of trading.
Harvard Bioscience Inc [HBIO]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Harvard Bioscience Inc [HBIO] shares currently have an operating margin of -3.99% and a Gross Margin at 51.36%. Harvard Bioscience Inc’s Net Margin is presently recorded at -64.68%.
Harvard Bioscience Inc (HBIO) Capital Structure & Debt Analysis
According to recent financial data for Harvard Bioscience Inc. ( HBIO), the Return on Equity (ROE) stands at -138.36%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -54.93%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Harvard Bioscience Inc’s Return on Invested Capital (ROIC) is -252.56%, showcasing its effectiveness in deploying capital for earnings.
Harvard Bioscience Inc (HBIO) Efficiency & Liquidity Metrics
Based on Harvard Bioscience Inc’s (HBIO) latest financial statements, the Debt-to-Equity Ratio is 2.75%, indicating its reliance on debt financing relative to shareholder equity.
Harvard Bioscience Inc (HBIO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Harvard Bioscience Inc. (HBIO) effectively leverages its workforce, generating an average of -$161718.31 per employee. The company’s liquidity position is robust, with a Current Ratio of 0.81% and a Quick Ratio of 0.41%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Harvard Bioscience Inc [HBIO] stock
With the latest financial reports released by the company, Harvard Bioscience Inc posted -0.02/share EPS, while the average EPS was predicted by analysts to be reported at 0.01/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.04. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HBIO.
Harvard Bioscience Inc [HBIO]: Institutional Ownership
There are presently around $54.76%, or 60.89%% of HBIO stock, in the hands of institutional investors. The top three institutional holders of HBIO stocks are: BLACKROCK INC. with ownership of 2.84 million shares, which is approximately 6.5392%. PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC., holding 2.77 million shares of the stock with an approximate value of $$7.9 million in HBIO stocks shares; and PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC., currently with $$7.29 million in HBIO stock with ownership which is approximately 5.8812%.
